Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 1;77(2):210-214.
doi: 10.1001/jamaneurol.2019.3292.

Association of Seropositivity to Borrelia burgdorferi With the Risk of Neuropsychiatric Disorders and Functional Decline in Older Adults: The Aging Multidisciplinary Investigation Study

Virgilio Hernández Ruiz  1   2 , Arlette Edjolo  1 , Claire Roubaud-Baudron  3 , Benoît Jaulhac  4 , José-Alberto Avila-Funes  1   2 , Jean-François Dartigues  1 , Hélène Amieva  1 , Karine Pérès  1
Affiliations

Association of Seropositivity to Borrelia burgdorferi With the Risk of Neuropsychiatric Disorders and Functional Decline in Older Adults: The Aging Multidisciplinary Investigation Study

Virgilio Hernández Ruiz et al. JAMA Neurol. .

Abstract

Importance: Exposure to Borrelia burgdorferi (Bb) has been reported to be associated with certain neuropsychiatric disorders.

Objective: To establish the association between seropositivity to Bb and incidental neuropsychiatric disorders (eg, cognitive decline, incident dementia, and depressive symptoms) as well as functional decline.

Design, setting, and participants: This prospective, 6-year follow-up cohort study was conducted in a rural southwestern region of France and included 689 retired farmers 65 years or older randomly recruited from the Farmer Health Insurance System who agreed to submit a blood sample and were participants in the Aging Multidisciplinary Investigation study, an ongoing epidemiological prospective study of aging initiated in 2007. The data were analyzed from April to May 2019.

Exposures: Borrelia burgdorferi serology testing was performed in a 2-tiered approach. During the follow-up period, cognitive decline, incident dementia, depressive symptoms, and functional decline were repeatedly assessed.

Main outcomes and measures: Diagnosis of dementia relied on a 3-step procedure; cognitive decline was determined using the Mini-Mental State Examination and depressive symptomatology was assessed using the Center for Epidemiologic Studies Depression scale. For disability, scores on instrumental and basic activities of daily living were investigated.

Results: Of 689 participants, 432 (62.2%) were men and the mean (SD) age was 75.8 (6.4) years. The seroprevalence rate of Bb was 6.5%. At baseline, compared with Bb- participants, those who were Bb+ were older, predominantly men, and had lower depressive symptoms. No association between seropositivity and any of the studied outcomes (ie, cognitive decline, depressive symptoms, or functional decline) was found in the crude analysis and after adjusting for confounding variables. Regarding incident dementia, no increased risk was found among Bb+ participants (hazard ratio, 0.42; 95% CI, 0.1-1.17; adjusted for diverse confounders).

Conclusions and relevance: To our knowledge, this is one of the few longitudinal studies exploring the risk of neuropsychiatric disorders and functional decline associated with exposure to Bb. Despite its limitations (eg, a lack of information if clinical manifestations of Lyme borreliosis existed, date of exposure, or treatment received), this study suggests that seropositivity to Bb is not a risk factor for incidental neuropsychiatric disorders and functional decline.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Jaulhac reported grants from Inserm, France during the conduct of the study. Dr Dartigues reported grants from Roche outside the submitted work. No other disclosures were reported.

Similar articles

See all similar articles

Cited by

References

    1. Hu LT. Lyme disease. Ann Intern Med. 2016;164(9):ITC65-ITC80. doi:10.7326/AITC201605030 - DOI - PubMed
    1. Ross Russell AL, Dryden MS, Pinto AA, Lovett JK. Lyme disease: diagnosis and management. Pract Neurol. 2018;18(6):455-464. doi:10.1136/practneurol-2018-001998 - DOI - PubMed
    1. Sanchez JL. Clinical manifestations and treatment of Lyme disease. Clin Lab Med. 2015;35(4):765-778. doi:10.1016/j.cll.2015.08.004 - DOI - PubMed
    1. Blanc F. Epidemiology of Lyme borreliosis and neuroborreliosis in France [in French]. Rev Neurol (Paris). 2009;165(8-9):694-701. doi:10.1016/j.neurol.2009.04.001 - DOI - PubMed
    1. Wilking H, Stark K. Trends in surveillance data of human Lyme borreliosis from six federal states in eastern Germany, 2009-2012. Ticks Tick Borne Dis. 2014;5(3):219-224. doi:10.1016/j.ttbdis.2013.10.010 - DOI - PubMed

Publication types